MONMOUTH JUNCTION, N.J., Feb. 18, 2016 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it will exhibit at the 45th Society of Critical Care Medicine (SCCM) Congress in Orlando, Florida, from February 20-24, 2016 in Booth #827 at the Orange County Convention Center.
As part of the conference agenda, Dr. Kai Singbartl, MD, MPH, from the PennState Milton S. Hershey Medical Center, Hershey, Pennsylvania, will give a talk entitled, "CytoSorbents Filter for Removal of Pro-inflammatory Cytokines" on Tuesday, February 23, 2016 at 11AM ET.
In addition, the abstract entitled, "Combination ECMO and Cytokine Adsorption Therapy for Severe Sepsis with Cardiogenic Shock and ARDS", authored by Dr. Nicholas J. Lees, et. al., from Harefield NHS Foundation Trust Hospital, Harefield, United Kingdom, was published in a conference companion issue of Critical Care Medicine, the official journal of the SCCM. This case report describes an otherwise healthy 33 year woman, who 5 months after giving birth, contracted H1N1 Influenza and Staphylococcus aureus pneumonia, which tested positive for the deadly Panton-Valentine leukocidin (PVL) toxin. Despite antibiotics and standard of care therapy, she rapidly became septic with low cardiac output shock and acute respiratory distress syndrome, one of the most severe forms of lung injury. She was then transferred from an outside hospital, failing high vasopressor support and mechanical ventilation. Treatment with venoarterial extracorporeal membrane oxygenation (ECMO) and cytokine reduction with CytoSorb® for 24 hours, in addition to intravenous immunoglobulin G therapy and antibiotics, helped to stabilize the patient, with a gradual improvement in oxygenation, and a complete weaning of vasopressors after 12 hours of therapy. She ultimately went on to survive and make a complete recovery, with a return of normal heart and lung function.
"We are pleased to report yet another example of how CytoSorb® is helping to save lives and keep families together." stated Dr. Phillip Chan, CEO of CytoSorbents.
CytoSorb® is approved in the European Union, but not yet approved in the United States.
The Society of Critical Care Medicine (SCCM) is a non-profit organization that represents nearly 16,000 highly trained professionals in more than 100 countries whose collective goal is to secure the highest quality care for all critically-ill and injured patients. The SCCM envisions a day when all such patients are cared for by a dedicated team of physicians, nurses, and other medical professionals specifically trained in critical care. The organization publishes Critical Care Medicine, the premier peer-reviewed, scientific journal in critical care, as well as Pediatric Critical Care Medicine, the first scientific, peer-reviewed journal to focus exclusively on pediatric and neonatal critical care.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorb® is approved in the European Union with distribution in 32 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used safely in more than 9,000 human treatments to date.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's websites: http://www.cytosorbents.com and http://www.cytosorb.com
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2015, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
SOURCE CytoSorbents Corporation